Apnimed, Inc.
APMDHealthcare|Biotechnology|US
$15.10
+0.94 (+6.64%)
Clinical Trials (19)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04394143 Effect of AD128 to Treat Obstructive Sleep Apnea | Sleep Apnea, Obstructive | P2P3 | Completed | 15 | RCT, Double-blind | AD128, Mannitol |
| NCT06566820 Continuation Protocol for Obstructive Sleep Apnea (OSA) | OSA | P3 | By Invite | 1,280 | Open-label | Aroxybutynin and Atomoxetine |
| NCT05811247 Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo) | OSA | P3 | Completed | 660 | RCT, Double-blind | AD109, Placebo |
| NCT05813275 Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study) | OSA | P3 | Completed | 646 | RCT, Double-blind | AD109, Placebo |
| NCT05448443 Study of AD981 Versus Placebo in Obesity Hypoventilation Syndrome | Obesity Hypoventilation Syndrome (OHS) | P2 | Completed | 15 | RCT, Double-blind | AD981 |
| NCT04449133 Study of AD128 Versus Placebo in Obstructive Sleep Apnea | Obstructive Sleep Apnea | P2 | Completed | 20 | RCT, Double-blind | AD128, Placebo |
| NCT04645524 Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea | Obstructive Sleep Apnea | P2 | Completed | 15 | RCT, Double-blind | AD182, AD504, Placebo |
| NCT04905979 Trial of AD113 and Atomoxetine in OSA Patients With Hypertension | Obstructive Sleep Apnea, Hypertension | P2 | Completed | 21 | RCT, Double-blind | AD113, Atomoxetine |
| NCT03845023 Trial of AD036 in Obstructive Sleep Apnea | Obstructive Sleep Apnea | P2 | Completed | 140 | RCT, Double-blind | AD036 Dose 1, AD036 Dose 2, AD036 Dose 3, Placebo |
| NCT04580394 Crossover Trial of AD109 in Obstructive Sleep Apnea | Obstructive Sleep Apnea | P2 | Completed | 60 | RCT, Double-blind | AD109, Atomoxetine, R-oxybutynin, Placebo |
| NCT04631107 AD109 Dose Finding in Mild to Moderate OSA | Obstructive Sleep Apnea | P2 | Completed | 32 | RCT, Double-blind | AD109 dose1- A, AD109 dose2- B, Placebo- C |
| NCT03892772 Combination Pharmacological Interventions for Multiple Mechanisms of Obstructive Sleep Apnea | Sleep Apnea | P1P2 | Completed | 23 | RCT, Double-blind | SAS0421a, SAS0421b, SAS0421c, placebo |
| NCT04611750 Pharmacological Intervention for Symptomatic Mild Sleep Disordered Breathing | Sleep Disordered Breathing | P2 | Completed | 53 | RCT, Double-blind | AD036, Placebo |
| NCT05101122 Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED) | Obstructive Sleep Apnea | P1P2 | Completed | 15 | Open-label | Dosing 1: Atomoxetine, AD313 |
| NCT04445688 Crossover Trial of AD036 in Obstructive Sleep Apnea | Obstructive Sleep Apnea | P2 | Completed | 62 | RCT, Double-blind | AD036, Atomoxetine, Placebo |
| NCT05793684 AD816 Crossover Study | OSA, Obstructive Sleep Apnea | P2 | Completed | 25 | RCT, Double-blind | Period A, Period B, Period C |
| NCT05071612 Parallel Arm Trial of AD109 and AD504 In Patients With OSA | OSA - Obstructive Sleep Apnea | P2 | Completed | 294 | RCT, Double-blind | AD109, AD504, Atomoxetine Hydrochloride, Placebo |
| NCT06400615 Study That Tests AD109 in Patients Taking GLP-1 Drugs | OSA | P2 | Completed | 40 | RCT, Open-label | AD109 |
| NCT06525337 Adherence to Health Coaching with Wearable Devices: Enhancing Patient Engagement and Outcomes | Obstructive Sleep Apnea | N/A | Unknown | 60 | RCT, Single-blind | — |